在NAFLD/NASH中,额外肝脏和肝脏系统的交叉交叉
Yiliang Duan1, Yan Yang2, Shuqiang Zhao3
1Jiangsu Key Laboratory of Druggability of Biopharmaceuticals and State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, China.
概括
非酒精性脂肪肝 (NAFLD) 是一个全球性的健康问题. 了解其原因,包括饮食和细胞相互作用,是开发非酒精性脂肪肝炎 (NASH) 新疗法的关键.
科学领域:
- 肝病学和代谢障碍 肝病和代谢障碍
- 细胞和分子生物学 细胞和分子生物学
背景情况:
- 非酒精性脂肪性肝病 (NAFLD) 是全球最常见的慢性肝病.
- 非酒精性脂肪肝炎 (NASH) 是一种严重的NAFLD形式,可以在没有干预的情况下导致肝硬化或肝癌.
- 目前对NAFLD/NASH病变的理解尚不完整,这限制了有效的药理疗法.
研究的目的:
- 审查和分类影响NAFLD/NASH的肝脏内外因素.
- 详细阐述推动NAFLD/NASH发病和进展的机制.
- 探索NAFLD/NASH病因学的进展,并确定潜在的治疗点.
主要方法:
- 文献综述对NAFLD的影响进行了分类.
- 病原性机制的详细检查.
- 在NAFLD发展中对器官间和细胞间相互作用的分析.
主要成果:
- NAFLD病因涉及外部因素 (饮食,环境,性别) 和内部相互作用.
- 疾病的发展与营养代谢,胰岛素抵抗和肝肠轴有关.
- 肝内部相互作用包括肝细胞,库弗弗细胞 (KCs) 和肝星细胞 (HSCs).
结论:
- 对NAFLD/NASH病原体的全面理解对于开发未来疗法至关重要.
- 针对代谢失调和细胞交叉通话提供了有前途的治疗途径.
- 需要进一步研究NAFLD/NASH因素的复杂相互作用.
相关概念视频
Diseases of the Liver and Gallbladder
527
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
527
Ultrasound II: Endoscopic Ultrasound and FibroScan
101
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
101
Hepatic Drug Excretion: Enterohepatic Cycling
1.5K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.5K
Hepatic Portal System
1.2K
The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
1.2K
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
117
Hepatic clearance refers to the volume of blood cleared of a drug by the liver per unit of time. It plays a crucial role in drug metabolism and elimination. While hepatic clearance is commonly estimated by subtracting renal clearance from total body clearance, other pathways, such as pulmonary or biliary clearance, may also contribute. However, these pathways are generally less significant than hepatic and renal clearance.
Most drugs undergo restrictive clearance, which is proportional to the...
Most drugs undergo restrictive clearance, which is proportional to the...
117
Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K


